Seattle Genetics (SGEN) Tops Q4 EPS by 2c

Seattle Genetics (NASDAQ: SGEN) reported Q4 EPS of ($0.18), $0.02 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $93.5 million versus the consensus estimate of $88.28 million.

“In 2015, we demonstrated significant progress across our corporate priorities. For ADCETRIS, we achieved record sales in the fourth quarter and for the year, received FDA approval for an expanded label, completed enrollment in two of three ongoing phase 3 trials and continued our efforts to establish ADCETRIS as the foundation of care for CD30-expressing lymphomas,” saidClay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “We also showed substantial progress with our pipeline. We plan to initiate a phase 3 trial with 33A in acute myeloid leukemia later this year, and we are advancing more than a dozen other clinical and preclinical programs in development for a range of hematologic malignancies and solid tumors. With a strong financial position, we are well-positioned to continue delivering on our aggressive commercial, clinical and research goals.”

For earnings history and earnings-related data on Seattle Genetics (SGEN) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• Teradyne (TER) Tops Q1 EPS by 18c
• O'Reilly Automotive (ORLY) Misses Q1 EPS by 7c, Offers Guidance